dactolisib and Body-Weight

Due to the high relapse rate and toxicity of the common therapies in patients with acute myeloid leukemia (AML), modifications in the treatment strategies are required. The present study was conducted to determine the effects of combinational therapy with a dual PI3K/mTOR inhibitor, BEZ235, and TLR7/8 agonist, R848, on murine AML model.. BEZ235 and R848 were administered to AML leukemic mice in either a single or combination treatment. Frequency of T-CD4. Following combinational therapy with BEZ235 and R848, increasing in the frequency of anti-tumor immune cells including T-CD4. Taken together, we indicated that the combinational therapy with BEZ235 and R848 could be considered as a potential and powerful therapeutic option for AML patients. Further clinical studies are required to expand our current findings.

Topics: Adjuvants, Immunologic; Animals; Body Weight; Disease Models, Animal; Humans; Leukemia, Myeloid, Acute; Mice; Phosphatidylinositol 3-Kinases; Toll-Like Receptor 7